FY2024 EPS Estimates for Marinus Pharmaceuticals, Inc. Decreased by Cantor Fitzgerald (NASDAQ:MRNS)

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) – Research analysts at Cantor Fitzgerald lowered their FY2024 earnings per share estimates for shares of Marinus Pharmaceuticals in a research note issued to investors on Tuesday, April 16th. Cantor Fitzgerald analyst C. Duncan now anticipates that the biopharmaceutical company will post earnings per share of ($2.32) for the year, down from their previous estimate of ($2.13). Cantor Fitzgerald has a “Overweight” rating and a $28.00 price target on the stock. The consensus estimate for Marinus Pharmaceuticals’ current full-year earnings is ($2.37) per share.

Marinus Pharmaceuticals (NASDAQ:MRNS) last issued its quarterly earnings results on Tuesday, March 5th. The biopharmaceutical company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.10). The company had revenue of $7.19 million for the quarter, compared to analyst estimates of $7.78 million. Marinus Pharmaceuticals had a negative return on equity of 269.75% and a negative net margin of 456.31%. During the same period in the prior year, the company earned ($0.76) EPS.

Other equities research analysts have also recently issued research reports about the company. Royal Bank of Canada reissued a “sector perform” rating and issued a $3.00 price target (down previously from $24.00) on shares of Marinus Pharmaceuticals in a research note on Monday. Truist Financial decreased their price objective on shares of Marinus Pharmaceuticals from $25.00 to $10.00 and set a “buy” rating for the company in a research report on Wednesday. Robert W. Baird reiterated a “neutral” rating on shares of Marinus Pharmaceuticals in a report on Tuesday. Oppenheimer reissued a “market perform” rating and issued a $9.00 price objective on shares of Marinus Pharmaceuticals in a research note on Thursday, March 7th. Finally, StockNews.com downgraded Marinus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, March 6th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $16.07.

Marinus Pharmaceuticals Stock Down 2.1 %

Shares of NASDAQ MRNS opened at $1.41 on Thursday. The stock has a market capitalization of $77.45 million, a P/E ratio of -0.54 and a beta of 0.91. The stock’s fifty day moving average is $8.55 and its 200 day moving average is $8.40. Marinus Pharmaceuticals has a 52 week low of $1.11 and a 52 week high of $11.26. The company has a debt-to-equity ratio of 5.68, a quick ratio of 4.01 and a current ratio of 4.07.

Hedge Funds Weigh In On Marinus Pharmaceuticals

A number of institutional investors have recently modified their holdings of the company. FMR LLC lifted its position in Marinus Pharmaceuticals by 1,887.9% in the 1st quarter. FMR LLC now owns 4,433 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 4,210 shares in the last quarter. BluePath Capital Management LLC purchased a new position in shares of Marinus Pharmaceuticals during the third quarter valued at approximately $38,000. Quantbot Technologies LP bought a new stake in Marinus Pharmaceuticals during the first quarter worth $40,000. Ameritas Investment Partners Inc. purchased a new stake in Marinus Pharmaceuticals in the 2nd quarter valued at $45,000. Finally, Jane Street Group LLC bought a new position in Marinus Pharmaceuticals during the 4th quarter valued at $47,000. 98.80% of the stock is owned by institutional investors and hedge funds.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.